Standout Papers
Citation Impact
Citing Papers
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
2004
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
2012
Cell entry mechanisms of SARS-CoV-2
2020 Standout
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism
2009 StandoutScienceNobel
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Myasthenia Gravis
2016 Standout
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
New therapies for treatment of rheumatoid arthritis
2007
Rheumatoid arthritis
2016 Standout
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
Comparison of Combination Plasmapheresis/IVIg/ Anti-CD20 Versus High-Dose IVIg in the Treatment of Antibody-Mediated Rejection
2009
Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategy
1999
Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. Molecular genetic evidence of the same clonal origin.
1988 StandoutNobel
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab
2004
Methods for comprehensive identification of membrane proteins recognized by a large number of monoclonal antibodies
2009
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
2013 Standout
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
2004 Standout
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
2009 StandoutNature
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
2006
Role of the retinoblastoma protein in the pathogenesis of human cancer.
1997 StandoutNobel
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008 Standout
Multiple sclerosis
2008 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Evolving concepts of rheumatoid arthritis
2003 StandoutNature
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
2006
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
2014
Graves' Ophthalmopathy
2010 Standout
Rituximab as Treatment for Refractory Kidney Transplant Rejection
2004
Immune Thrombocytopenic Purpura
2002 Standout
Systemic Lupus Erythematosus
2011 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
1997 Standout
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
2020 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis
1999
Immune cell transcriptome datasets reveal novel leukocyte subset–specific genes and genes associated with allergic processes
2006
Prospects for the use of NK cells in immunotherapy of human cancer
2007
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
2009
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
2000 Standout
Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells
2002
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies?
2002
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
2002
Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study
2010
Immunosuppressive Drugs for Kidney Transplantation
2004 Standout
Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies
2008
Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer
1996
Structural basis of receptor recognition by SARS-CoV-2
2020 StandoutNature
Atg9 Vesicles Recruit Vesicle-tethering Proteins Trs85 and Ypt1 to the Autophagosome Formation Site
2012 StandoutNobel
The B-cell receptor of a hepatitis C virus (HCV)–associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis
2001
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
2014 StandoutNobel
Synergistic interaction between cisplatin and gemcitabine in vitro.
1996
Isolation of a candidate human hematopoietic stem-cell population.
1992
Long-Term Lymphohematopoietic Reconstitution by a Single CD34-Low/Negative Hematopoietic Stem Cell
1996 StandoutScience
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
2005 StandoutScience
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
1998
Cancer Cell Cycles
1996 StandoutScience
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
1994
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
2000
A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
2008
Drug Discovery: A Historical Perspective
2000 StandoutScience
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
2008
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
1997
The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice
2005
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
1999 Standout
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
2001
Effects of Human Anti-Spike Protein Receptor Binding Domain Antibodies on Severe Acute Respiratory Syndrome Coronavirus Neutralization Escape and Fitness
2014
Lineage promiscuity in hemopoietic differentiation and leukemia
1986
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma
2001
Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
1999
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
2002
European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma
2000
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of RA Newman being referenced
2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation
1993
Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts
1983
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
1994 Standout
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
1994
Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study
1993
Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study
1993